NCT07106762Phase 2Listed as recruiting
Metastatic urothelial cancer after immunotherapy: a new medicine compared with platinum-based chemotherapy
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Minimum age: 18 years
Centres in: Cluj-Napoca · Craiova · Iași
See all centres (3)Hide the centre list
These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.
Central study contact
To find the team and exact institution in your chosen city, quote study NCT07106762. This contact may be in another country; ask which language you can use.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286 (dialling format unconfirmed)
First line of the email MUST contain NCT # and Site #.
Source: study registry
Cluj-Napoca
Institutul Oncologic Cluj
Contact for this study
Source: study registry
Craiova
Centrul de Oncologie "Sfântul Nectarie"
Contact for this study
Source: study registry
Iași
Institutul Regional de Oncologie
Contact for this study
Source: study registry
Who can take part
Metastatic urothelial cancer after immunotherapy: a new medicine compared with platinum-based chemotherapy
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
- Minimum age:
- 18 years
- Maximum age:
- Not specified in the record consulted
- Participant sex, as recorded in the registry:
- All sexes
This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.
Criteria published in the registry — English original
Inclusion Criteria: * Participants must have histologically confirmed advanced urothelial carcinoma. * Participants must be eligible to receive platinum-based chemotherapy. * Participants must be Anti-PD-(L)1-experienced (in locally advanced or metastatic setting), either in combination with or sequential to another systemic therapy. * Participants treated only in the peri-operative setting must have relapsed within 12 months of the last dose of the treatment. * Participants must have ≥ 1 measurable lesion per RECIST v1.1. * Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. Exclusion Criteria: * Participants must not have platinum-based chemotherapy exposure within 12 months. * Participants must not have received \>2 prior regimens irrespective of the setting. * Participants must not have prior ADC therapy targeting EGFR or HER3. * Participants must not have prior therapy with topoisomerase 1 inhibitor. * Participants must not have active, untreated brain metastases. * Other protocol-defined inclusion/exclusion criteria apply.
What taking part involves
Participants are randomly assigned to the study groups.
These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.
Group 1 · Studied intervention
Iza-bren
Group 2 · Studied intervention
Iza-bren
Group 3 · Active treatment comparison
Cisplatin · Gemcitabine · Carboplatin
Group 4 · Studied intervention
Iza-bren
Group 5 · Active treatment comparison
Cisplatin · Gemcitabine · Carboplatin
- Start of the whole study
- 30 September 2025
- Completion of the whole study
- 18 November 2033 (estimated)
These are global study dates, not an individual's participation duration or an enrolment deadline.
Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.
Ask the study team before travelling:
- whether places are available at the chosen centre and how the first assessment is arranged
- how often you need to attend the centre and whether a hospital stay is necessary
- whether travel or accommodation costs are covered and under what conditions
- which documents you need to prepare and whether a family member or carer can accompany you
Original registry title
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Updated in the registry: 29 July 2026
Data consulted: 19 November 2026
See the official record ↗If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.
